FDA.reportPublic FDA data

POLYETHYLENE GLYCOL 3350

Substance profile for UNII G2M7P15E5P, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Substance Identity#

UNII
G2M7P15E5P
Preferred term
POLYETHYLENE GLYCOL 3350
Registry number
25322-68-3
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
Polymer substance not supported

Chemical And Database Identifiers#

RxCUI
221147
PubChem
0
NCIt
C80131
INN ID
0

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
RxNorm221147mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=221147
NCI ThesaurusC80131ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C80131
FDA Substance Registration SystemG2M7P15E5Pprecision.fda.gov/uniisearch/srs/unii/G2M7P15E5P

DailyMed Socrata Ingredients#

Type, DailyMed label, SPL version table
TypeDailyMed labelSPL version
INACTIVE INGREDIENTESZOPICLONE1
INACTIVE INGREDIENT085a57b6-75f5-4ecc-b831-11383f5f68a73
INACTIVE INGREDIENTc4104df9-2f42-45ed-bf26-112ec418cd6b1
INACTIVE INGREDIENTL-METHYLFOLATE CALCIUM 7.5mg Tablets L-METHYLFOLATE CALCIUM 15mg Tablets4
INACTIVE INGREDIENTLOSARTAN POTASSIUM TABLETS USP 7364 7365 7366 Rx only17
INACTIVE INGREDIENTHydroxychloroquine Sulfate Tablets, USP2
INACTIVE INGREDIENTHYDROXYZINE HYDROCHLORIDE TABLETS, USP Rx only3
INACTIVE INGREDIENTThese highlights do not include all the information needed to use divalproex sodium delayed-release tablets, USP safely and effectively. See full prescribing information for divalproex sodium delayed-release tablets, USP. DIVALPROEX sodium delayed-release tablets, USP for oral use Initial U.S. Approval: 19831
INACTIVE INGREDIENTedf29e02-f3db-4954-9a1a-9f153f9a073f2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use BUPROPION HYDROCHLORIDE safely and effectively. See full prescribing information for BUPROPION HYDROCHLORIDE. BUPROPION HYDROCHLORIDE extended-release tablets, USP (SR) for oral use Initial U.S. Approval: 19852
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTPHENELZINE SULFATE TABLETS, USP Novel Laboratories, Inc. Rx Only2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use RECOTHROM safely and effectively. See full prescribing information for RECOTHROM. RECOTHROM, Thrombin topical (Recombinant) Lyophilized Powder for Solution - For Topical Use Only Initial U.S. Approval: 20088
INACTIVE INGREDIENTFalessa Kit5
INACTIVE INGREDIENT2666b95e-667f-471a-9929-9deca27e9cbc2
INACTIVE INGREDIENTDelsym 12 Hour Cough Relief Grape for Children and Adults4
INACTIVE INGREDIENTDelsym 12 Hour Cough Relief Orange for Children & Adults4
INACTIVE INGREDIENTFluocinonide Cream USP, 0.05% Fluocinonide Cream USP, 0.05% (Emulsified Base) Fluocinonide Gel USP, 0.05% Fluocinonide Ointment USP, 0.05%2
INACTIVE INGREDIENTf398f8a9-92f3-47cb-81c2-6078806a464d4
INACTIVE INGREDIENTMetoprolol Tartrate Tablets USP Rx Only Prescribing Information7
INACTIVE INGREDIENTabebf252-4ee0-46fb-a969-5ef0a4da414b3
INACTIVE INGREDIENTe47d3094-109e-4295-9833-d1808adfe6e11
INACTIVE INGREDIENTHydroxychloroquine Sulfate Tablets, USP1
INACTIVE INGREDIENT1be6cd7a-3f9c-4661-85e4-4a310b490ad33
ACTIVE MOIETYbcd57d3c-e1c4-474f-a757-ca89b020278b1
ACTIVE INGREDIENTbcd57d3c-e1c4-474f-a757-ca89b020278b1
INACTIVE INGREDIENT2f764009-5405-4ff5-8223-12d2aedeb2ad2
INACTIVE INGREDIENT5991bbb4-754f-489e-9708-1ca1b6a4280f2
INACTIVE INGREDIENT6069e9dd-3549-40cd-9bdc-c702293aa8e32
INACTIVE INGREDIENT8aeb1434-6a8a-4ac1-9c9a-b488bd4831192
INACTIVE INGREDIENTDrug Facts9
INACTIVE INGREDIENTDrug Facts7
INACTIVE INGREDIENTBupropion Hydrochloride Extended-Release Tablets, USP (SR)2
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. ISENTRESS ® (raltegravir) Film-Coated Tablets, for oral use ISENTRESS ® (raltegravir) Chewable Tablets, for oral use Initial U.S. Approval: 20072
INACTIVE INGREDIENTDrug Facts4
INACTIVE INGREDIENTf23a3dc4-62e9-46d0-a4b7-383dd5e029111
INACTIVE INGREDIENTd327b4ea-a232-4102-bd74-141196f687e08
INACTIVE INGREDIENTThese highlights do not include all the information needed to use ATRIPLA safely and effectively. See full prescribing information for ATRIPLA. ATRIPLA ® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 20063
INACTIVE INGREDIENTThese highlights do not include all the information needed to use simvastatin tablets USP safely and effectively. See full prescribing information for simvastatin tablets USP. SIMVASTATIN tablets USP for oral use Initial U.S. Approval: 19911
INACTIVE INGREDIENTDrug Facts7
INACTIVE INGREDIENTThese highlights do not include all the information needed to use amoxicillin tablets safely and effectively. See full prescribing information for amoxicillin tablets, USP. Amoxicillin Tablets, USP Initial U.S. Approval: 1974 To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin tablets, USP and other antibacterial drugs, amoxicillin tablets, USP should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use PREZISTA safely and effectively. See Full Prescribing Information for PREZISTA. PREZISTA (darunavir) Oral Suspension, for Oral use PREZISTA (darunavir) Tablet, Film Coated for Oral use Initial U.S. Approval – 20062
INACTIVE INGREDIENTThese highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir/ritonavir) Tablet, Film Coated for Oral use KALETRA (lopinavir/ritonavir) Solution for Oral use Initial U.S. Approval: 20001
INACTIVE INGREDIENTHydroxychloroquine Sulfate Tablets, USP2
INACTIVE INGREDIENTFlunisolide Nasal Solution USP, 0.025%1
INACTIVE INGREDIENTLOSARTAN POTASSIUM TABLETS USP 7364 7365 7366 Rx only7
INACTIVE INGREDIENTThese highlights do not include all the information needed to use KEPPRA ® safely and effectively. See full prescribing information for KEPPRA. KEPPRA (levetiracetam) tablets, for oral use KEPPRA (levetiracetam) oral solution Initial U.S. Approval: 19993
INACTIVE INGREDIENTPatterson Topical Anesthetic Strawberry Flavor1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir and ritonavir) Tablet, Film Coated for Oral use KALETRA (lopinavir and ritonavir) Solution for Oral use Initial U.S. Approval: 20002
INACTIVE INGREDIENTGemfibrozil Tablets USP, 600 mg Tablet, Film Coated Rx Only2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. ISENTRESS ® (raltegravir) Film-Coated Tablets, for oral use ISENTRESS ® (raltegravir) Chewable Tablets, for oral use Initial U.S. Approval: 20072
INACTIVE INGREDIENTDEPO-MEDROL ® methylprednisolone acetate injectable suspension, USP1
INACTIVE INGREDIENTHYDROXYZINE HYDROCHLORIDE TABLETS, USP1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Azor safely and effectively. See full prescribing information for Azor. Azor (amlodipine and olmesartan medoxomil) tablet, film coated for oral use Initial U.S. Approval: 20075
INACTIVE INGREDIENTTEVETEN ® HCT (eprosartan mesylate/hydrochlorothiazide)600/12.5mg 600/25mg2
INACTIVE INGREDIENTbe65d31a-87c1-4f37-a55d-7395bfe3642a2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Medroxyprogesterone Acetate Injectable Suspension, USP safely and effectively. See full prescribing information for Medroxyprogesterone Acetate Injectable Suspension, USP. Medroxyprogesterone Acetate Injectable Suspension, USP, for intramuscular use Initial U.S. Approval: 19597
ACTIVE INGREDIENTPolyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution2
ACTIVE MOIETYPolyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution2
ACTIVE INGREDIENTPolyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution1
ACTIVE MOIETYPolyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution1
INACTIVE INGREDIENTAmoxicillin Tablets, USP2
INACTIVE INGREDIENTMUPIROCIN OINTMENT USP, 2%1
INACTIVE INGREDIENTMethylPREDNISolone Acetate Injectable Suspension, USP1
ACTIVE INGREDIENTDrug Facts1
ACTIVE MOIETYDrug Facts1
INACTIVE INGREDIENTLevetiracetam Tablets1
INACTIVE INGREDIENTKEPPRA ® (levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg tablets 100 mg/mL oral solution1
INACTIVE INGREDIENTAllerNaze TM (triamcinolone acetonide, USP) nasal spray, 50 mcg1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use PREZISTA safely and effectively. See Full Prescribing Information for PREZISTA. PREZISTA (darunavir) Tablet, Film Coated for Oral use Initial U.S. Approval – 20063
INACTIVE INGREDIENTThese highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. ISENTRESS (raltegravir) Tablets Initial U.S. Approval: 20073
INACTIVE INGREDIENTLevetiracetam Tablets1
INACTIVE INGREDIENTRECOMBINATE [Antihemophilic Factor (Recombinant)]7
INACTIVE INGREDIENTTopical Anesthetic Banana Flavor Gel1
INACTIVE INGREDIENT76678031-5373-498b-b59d-195705e6ac694
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Ranexa safely and effectively. See full prescribing information for Ranexa. Ranexa (ranolazine) extended-release tablets Initial U.S. Approval: 20062
INACTIVE INGREDIENTBupropion Hydrochloride Extended-Release Tablets, USP (SR)4
INACTIVE INGREDIENTThese highlights do not include all the information needed to use AVALIDE safely and effectively. See full prescribing information for AVALIDE. AVALIDE (irbesartan and hydrochlorothiazide) tablet for oral use AVALIDE (irbesartan and hydrochlorothiazide) tablet, film coated for oral use Initial U.S. Approval: 19972
INACTIVE INGREDIENTHydroxychloroquine Sulfate Tablets, USP2
INACTIVE INGREDIENTTOLNAFTATE Antifungal Cream1
ACTIVE INGREDIENTAFFORDABLE PHARMACEUTICALS LLC PEG-3350 and Electrolytes1
ACTIVE MOIETYAFFORDABLE PHARMACEUTICALS LLC PEG-3350 and Electrolytes1
INACTIVE INGREDIENTMedroxyprogesterone Acetate Injectable Suspension, USP1
ACTIVE INGREDIENTPEG-3350 (240 g) and Electrolytes for Oral Solution, USP with flavor pack2
ACTIVE MOIETYPEG-3350 (240 g) and Electrolytes for Oral Solution, USP with flavor pack2
ACTIVE INGREDIENTPEG-3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution with Flavor pack2
ACTIVE MOIETYPEG-3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution with Flavor pack2
INACTIVE INGREDIENTMUPIROCIN OINTMENT USP, 2%1
ACTIVE INGREDIENTPOLYETHYLENE GLYCOL 3350 POWDER, FOR SOLUTION [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3858
ACTIVE MOIETYPOLYETHYLENE GLYCOL 3350 POWDER, FOR SOLUTION [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3858
INACTIVE INGREDIENTVENLAFAXINE HYDROCHLORIDE TABLET, EXTENDED RELEASE [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3320
INACTIVE INGREDIENTKALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.]1567
INACTIVE INGREDIENTNORVIR (RITONAVIR) TABLET, FILM COATED NORVIR (RITONAVIR) SOLUTION [ABBVIE INC.]1509
INACTIVE INGREDIENTTEVETEN HCT (EPROSARTAN MESYLATE AND HYDROCHLOROTHIAZIDE) TABLET [ABBVIE INC.]1449
INACTIVE INGREDIENTKALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED [PD-RX PHARMACEUTICALS, INC.]1405
INACTIVE INGREDIENTCHLOROQUINE PHOSPHATE (CHLOROQUINE PHOSPHATE) TABLET, FILM COATED [BRYANT RANCH PREPACK]1000
INACTIVE INGREDIENTCHLOROQUINE PHOSPHATE TABLET, FILM COATED [BRYANT RANCH PREPACK]1000
INACTIVE INGREDIENTGRALISE (GABAPENTIN) TABLET, FILM COATED [BRYANT RANCH PREPACK]1000
INACTIVE INGREDIENTVIEKIRA PAK (DASABUVIR AND OMBITASVIR AND PARITAPREVIR AND RITONAVIR) KIT [ABBVIE INC.]203
INACTIVE INGREDIENTMETFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) TABLET [REMEDYREPACK INC. ]58
INACTIVE INGREDIENTTECHNIVIE (OMBITASVIR AND PARITAPREVIR AND RITONAVIR) KIT [ABBVIE INC.]53
INACTIVE INGREDIENTMODERIBA (RIBAVIRIN) KIT MODERIBA (RIBAVIRIN) TABLET, FILM COATED [ABBVIE INC.]52
INACTIVE INGREDIENTISENTRESS (RALTEGRAVIR) TABLET, FILM COATED ISENTRESS (RALTEGRAVIR) TABLET, CHEWABLE ISENTRESS (RALTEGRAVIR) GRANULE, FOR SUSPENSION [MERCK SHARP & DOHME CORP.]49
INACTIVE INGREDIENTSIMVASTATIN TABLET, FILM COATED [INTERNATIONAL LABORATORIES, INC.]32
INACTIVE INGREDIENTPREZISTA (DARUNAVIR) TABLET, FILM COATED PREZISTA (DARUNAVIR) SUSPENSION [JANSSEN PRODUCTS LP]31
ACTIVE MOIETYMOVIPREP (POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE) KIT [SALIX PHARMACEUTICALS, INC.]30
ACTIVE INGREDIENTMOVIPREP (POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE) KIT [SALIX PHARMACEUTICALS, INC.]30
INACTIVE INGREDIENTZIDOVUDINE TABLET, FILM COATED [LANNETT COMPANY, INC.]29
INACTIVE INGREDIENTLEVETIRACETAM TABLET, FILM COATED, EXTENDED RELEASE [ACTAVIS PHARMA, INC.]23
INACTIVE INGREDIENTNOXAFIL (POSACONAZOLE) SUSPENSION NOXAFIL (POSACONAZOLE) TABLET, COATED NOXAFIL (POSACONAZOLE) SOLUTION [MERCK SHARP & DOHME CORP.]22
INACTIVE INGREDIENTLETAIRIS (AMBRISENTAN) TABLET, FILM COATED [GILEAD SCIENCES, INC]20
INACTIVE INGREDIENTSOLODYN (MINOCYCLINE HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [MEDICIS PHARMACEUTICAL CORP.]19
INACTIVE INGREDIENTATRIPLA (EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [BRISTOL MYERS SQUIBB & GILEAD SCIENCES, LLC]17
INACTIVE INGREDIENTMEDROXYPROGESTERONE ACETATE INJECTION, SUSPENSION [GREENSTONE LLC]17
INACTIVE INGREDIENTMETHYLPHENIDATE HYDROCHLORIDE TABLET, EXTENDED RELEASE [KREMERS URBAN PHARMACEUTICALS INC.]17
INACTIVE INGREDIENTSIMVASTATIN TABLET, FILM COATED [TEVA PHARMACEUTICALS USA INC]17
INACTIVE INGREDIENTXARELTO (RIVAROXABAN) TABLET, FILM COATED XARELTO (RIVAROXABAN) KIT [JANSSEN PHARMACEUTICALS, INC.]17
INACTIVE INGREDIENTDIVALPROEX SODIUM TABLET, DELAYED RELEASE [AUROBINDO PHARMA LIMITED]16
INACTIVE INGREDIENTJANUMET XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [MERCK SHARP & DOHME CORP.]16

Inactive Ingredient Database#

Browse recovered IID releases and source provenance.

Current IID rows for UNII G2M7P15E5P page 1 of 1 · 28 matching rows.

Ingredient, UNII, CAS table
IngredientUNIICASDosage formRoutePotencyMaximum daily exposure
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTIONINTRA-ARTICULAR56 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTION, SUSPENSIONINTRA-ARTICULAR56 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTION, SUSPENSIONINTRALESIONAL87 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTIONINTRAMUSCULAR56 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTION, SUSPENSIONINTRAMUSCULAR87 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTION, SUSPENSION, EXTENDED RELEASEINTRAMUSCULAR60 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTIONINTRASYNOVIAL3 %w/v
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTION, SUSPENSIONINTRASYNOVIAL87 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTIONINTRAVENOUS0.5 ml
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683SPRAY, METEREDNASAL96 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683CAPSULEORAL576 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683CAPSULE, EXTENDED RELEASEORAL51 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683SUSPENSIONORAL900 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683SUSPENSION, EXTENDED RELEASEORAL37 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683TABLETORAL52 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683TABLET, CHEWABLEORAL15 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683TABLET, COATEDORAL0.5 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683TABLET, DELAYED RELEASEORAL10 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683TABLET, EXTENDED RELEASEORAL61 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683TABLET, FILM COATEDORAL20 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683TABLET, ORALLY DISINTEGRATINGORAL0.16 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683SUPPOSITORYRECTAL5704 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTION, SUSPENSIONSOFT TISSUE87 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683INJECTION, SUSPENSIONSUBCUTANEOUS2.88 %w/v
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683SUSPENSIONSUBCUTANEOUS2.88 %w/v
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683CREAMTOPICAL396 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683OINTMENTTOPICAL1179 mg
POLYETHYLENE GLYCOL 3350G2M7P15E5P25322683SUPPOSITORYVAGINALNA